Worldwide Webinar Series:

Impact of Modeling & Simulation in Drug Development

Rosa’s Worldwide Webinar Series fosters the adoption of modeling and simulation by informing a broad audience about the strategic impact it can have on all aspects of research and development.

Since its inception in 2011, this complimentary monthly series has featured select speakers from academia, industry, Rosa client companies, and Rosa itself. The series has drawn many thousands of attendees worldwide from all drug development disciplines.

PLEASE NOTE - ***ALL WEBINARS PRIOR to 2017*** are available by contacting us CLICK HERE 

Sign up to receive Webinar and QSP News Alerts

Subscribe
Date Presenter / Topic Register

Andrew Goetz - Department of Biomedical Engineering, Yale University, New Haven, CT, US
Andrew is a biomedical engineering graduate student at Yale, studying cellular heterogeneity in signaling and metabolism under Purushottam Dixit. Andrew received his undergraduate degrees in applied mathematics and physics at Georgia Southern University. Andrew completed an industry internship at the biotech company Genentech under the supervision of Luca Gerosa, where he contributed to the development of systems pharmacology methods for targeted therapies of oncogenic signaling.

Computational modeling of in vitro anti-cancer drug combinations to inform dose selection in oncology clinical trials
More Info

Irina Kareva, PhD, Associate Director, Quantitative Pharmacology, EMD Serono (US-based Merck KGaA)
Irina Kareva received her PhD in Applied Mathematics for Life and Social Sciences from Arizona State University in 2012. Her research has been focused on mathematical modeling of cancer as an evolving ecological system, with particular focus on applying insights from ecology and evolution to understanding cancer initiation and progression. She did her post-doctoral fellowship at Tufts Medical Center in Boston, prior to joining EMD Serono (US business of Merck KGaA) in 2016, where she is currently an Associate Director in Quantitative Pharmacology Department. Dr. Kareva has co-authored 3 books and over 50 publications, and conducts both applied and basic research. Her current work is focused primarily on fit-for-purpose mechanistic modeling of compounds in immunology and immuno-oncology to enable rational safe and efficacious First-in-Human (FIH) dose projections both for monotherapy and combination therapy.

Guiding model-driven combination dose selection using multi-objective synergy optimization
More Info